Farmacovigilancia de vacunas para COVID-19

Name	Phase
*EU Nodes-AstraZeneca/Oxford COVID-19 vaccine	Phase 3 - completed/published
*Serum Institute of India COVID-19 vaccine	Phase 3 - completed/published
*SK BIO AstraZeneca/Oxford COVID-19 vaccine	Phase 3 - completed/published
Anhui Zhifei COVID-19 vaccine	Phase 3 - ongoing
Bharat Biotech COVID-19 vaccine	Phase 3 - ongoing/ partially published
Cansino COVID-19 vaccine	Phase 3 - ongoing/ partially published
Chumakov COVID-19 vaccine	Phase 1/2
CIGB COVID-19 vaccine	Phase 3 - ongoing
FBRI COVID-19 vaccine	Phase 1/2
Finlay Institute COVID-19 vaccine	Phase 3 - ongoing
Gamaleya/Sputnik light COVID-19 vaccine	Phase 3 - ongoing
Gamaleya/Sputnik V COVID-19 vaccine	Phase 3 - completed/published
Janssen COVID-19 vaccine	Phase 3 - completed
Kazakhstan RIBSP COVID-19 vaccine	Phase 3 - ongoing
Minhai Biotechnology COVID-19 vaccine	Phase 1/2
Moderna COVID-19 vaccine	Phase 3 - completed/published
Pfizer-BioNTech COVID‑19 Vaccine	Phase 3 - completed/published
Shifa Pharmed Industrial COVID-19 vaccine	Phase 1/2
Sinopharm-BBIBP COVID-19 vaccine	Phase 3 - ongoing/ partially published
Sinopharm-WIBP COVID-19 vaccine	Phase 3 - ongoing
Sinovac COVID-19 vaccine	Phase 3 - ongoing/ partially published
Takeda COVID-19 vaccine	Phase 1/2

Adopted Name	Name	EUL holder	Manufacturer	Effective date
Pfizer-BioNTech COVID-19 vaccine 2BNT162b2; Tozinameran; Comirnaty	Tozinameran - COVD-19 mRNA Vaccine COMIRNATY®	BioNTech Manufacturing GmbH, Germany	BioNTech Manufacturing GmbH, Germany	31 December 2020 (1)
EU Nodes-AstraZeneca/ Oxford COVID-19 vaccine; Vaxzevria in Europe (formerly AZD1222 and ChAdOx1)*	COVID-19 Vaccine (ChAdOx1-S ([recombinant])	AstraZeneca/SK Bioscience Co. Ltd, Republic of Korea	AstraZeneca/SK Bioscience Co. Ltd, Republic of Korea	15 February 2021 (2)
Serum Institute of India COVID-19 vaccine; Covishield in India*	COVID-19 Vaccine (ChAdOx1-S ([recombinant]) COVISHIELD™	Serum Institute of India Pvt. Ltd, India	Serum Institute of India Pvt. Ltd, India	15 February 2021 (3)
Janssen COVID-19 vaccine JNJ-78436735; Ad26.COV2-S (recombinant).	COVID-19 Vaccine (Ad26.COV2-S [recombinant])	Janssen–Cilag International NV, Belgium	Janssen–Cilag International NV, Belgium	12 March 2021 (4)
AstraZeneca/SK BIO COVID-19 vaccine*	COVID-19 Vaccine (ChAdOx1-S ([recombinant])	AstraZeneca AB, Sweden	Catalent Anagni; CP Pharmaceuticals;	15 April 2021 (5)
ModernaCOVID-19 vaccine mRNA-1273	COVID-19 mRNA Vaccine (nucleoside modified)	Moderna Biotech	Rovi Pharma Industrial Services, Spain	30 April 2021 (6)
Sinopharm/ BIBP COVID-19 vaccine Inactivated SARS-CoV-2-vaccine (Vero cell); BBIBP-CorV	COVID-19 Vaccine BIBP	Beijing Institute of Biological Products Co., Ltd. (BIBP)	Beijing, China	07 May 2021 (7)
Sinovac COVID-19 vaccine CoronaVac; adsorbed COVID-19 vaccine	COVD-19 mRNA Vaccine (vero cell) inactivated, CoronaVac	Sinovac Life Sciences Co., Ltd. China	Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R. China	01 june 2021 (8)

*Vaccines that have different authorizations, but with the same developer.

Updates

OFFICIAL REPORTS ON PHARMACOVIGILANCE PROGRAMS - 27 September 2021

U.S. Food and Drug Administration authorizes a booster dose of the Pfizer-BioNTech COVID-19 vaccine for certain populations

CDC Statement on recommendation of the Advisory Committee on Immunization Practices (ACIP)

Study on the risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since the first dose of COVID-19 vaccine administration

WHO authorizes extension of the shelf-life of Pfizer-BioNTech's Comirnaty vaccine

Chile's Institute of Public Health issues an information notice on the safety of Pfizer-BioNTech's COVID-19 vaccine following reports of myocarditis and pericarditis